Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VAL-339851 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| VAL-339851 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| VAL-339851 | BIOLOGICAL | Escalating dose levels |
| Placebo | OTHER | Saline |
Inclusion Criteria: * Agrees to comply with the study procedures and provides written informed consent * 18 to 49 years of age * Body mass index between 18 and 35 kg/m2 * Negative urine pregnancy test at the Screening visit and the day of each vaccination for females of childbearing potential. * Fe...
VAL-339851 is an investigational monoclonal antibody being developed for influenza. It is intended for use in the infectious disease therapeutic area. The drug is currently in Phase 1 clinical development and is not yet approved for any use.
VAL-339851 is being developed by Moderna, Inc., a biotechnology company traded on the NASDAQ under the ticker MRNA. The company is conducting clinical trials to evaluate the safety, tolerability, and immunogenicity of this investigational monoclonal antibody for influenza.
VAL-339851 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage clinical development.
VAL-339851 has one completed Phase 1 clinical trial, identified as NCT03345043. This study evaluated the safety, tolerability, and immunogenicity of VAL-339851 in healthy adult subjects in the United States. The trial enrolled 156 participants and was placebo-controlled, randomized, and double-blind.
VAL-339851 is the primary name for this investigational monoclonal antibody. No alternative names have been identified for this drug in the available information. It is being studied specifically for its potential use in influenza.